

Mario Tumbarello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6950505/publications.pdf>

Version: 2024-02-01

169
papers

11,268
citations

24978

57
h-index

32761

100
g-index

173
all docs

173
docs citations

173
times ranked

10124
citing authors

#	ARTICLE	IF	CITATIONS
1	XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?. <i>Antibiotics</i> , 2022, 11, 193.	1.5	3
2	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.5	10
3	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 827-840.	1.8	13
4	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac022.	0.9	17
5	Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients. <i>Journal of Fungi (Basel)</i> , <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5</i>	1.5	11
6	New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. <i>Antibiotics</i> , 2022, 11, 579.	1.5	31
7	Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. <i>Journal of Chemotherapy</i> , 2022, 34, 524-533.	0.7	3
8	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106611.	1.1	36
9	Efficacy of β -lactam/ β -lactamase inhibitors to treat extended-spectrum beta-lactamase-producing <i>Enterobacterales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-ESOT Project). <i>Transplant Infectious Disease</i> , 2021, 23, e13520.	0.7	10
10	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	2.0	4
11	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	2.9	130
12	<i>Staphylococcus aureus</i> ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis. <i>Critical Care</i> , 2021, 25, 197.	2.5	41
13	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: a SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. <i>Respiratory Medicine</i> , 2021, 190, 106674.	1.3	3
14	Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study. <i>Antibiotics</i> , 2021, 10, 1554.	1.5	1
15	Use of colistin in adult patients: A cross-sectional study. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 43-49.	0.9	29
16	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing <i>Enterobacterales</i> : The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , 2020, 20, 1629-1641.	2.6	17
17	Molecular Mechanisms, Epidemiology, and Clinical Importance of β -Lactam Resistance in <i>Enterobacteriaceae</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 5090.	1.8	60
18	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa233.	0.4	7

#	ARTICLE	IF	CITATIONS
19	(1,3)- β -D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. <i>Critical Care</i> , 2020, 24, 550.	2.5	30
20	Characterisation and risk factor profiling of <i>Pseudomonas aeruginosa</i> urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105900.	1.1	11
21	Meropenem/vaborbactam: a next generation β -lactam β -lactamase inhibitor combination. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 643-655.	2.0	64
22	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.4	49
23	Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. <i>Annals of Intensive Care</i> , 2020, 10, 94.	2.2	36
24	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4697-4711.	1.1	21
25	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 355-364.	2.9	265
26	Bloodstream infections caused by <i>Escherichia coli</i> in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. <i>PLoS ONE</i> , 2019, 14, e0224465.	1.1	27
27	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019, 79, 130-138.	1.7	67
28	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	2.5	123
29	Direct use of eazyplex [®] SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1055-1062.	1.1	11
30	Fungaemia in haematological malignancies: SEIFEM 2015 survey. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13083.	1.7	20
31	The role of carbapenem-resistant pathogens in cSSTI and how to manage them. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 113-122.	1.3	11
32	Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients. <i>Journal of Critical Care</i> , 2019, 50, 169-176.	1.0	18
33	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	1.1	120
34	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	1.3	11
35	Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 413-417.	1.3	12
36	Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry. <i>Journal of Chemotherapy</i> , 2019, 31, 9-14.	0.7	14

#	ARTICLE	IF	CITATIONS
37	Ceftolozane/tazobactam: place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 307-320.	2.0	100
38	Predictors of Mortality with <i>Staphylococcus aureus</i> Bacteremia in Elderly Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1284-1289.	1.3	18
39	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. <i>Journal of Chemotherapy</i> , 2018, 30, 157-171.	0.7	0
40	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	0.8	10
41	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 244-248.	1.1	55
42	Treatment and mortality of <i>Klebsiella pneumoniae</i> infections in critically ill patients: should we do and predict them better?. <i>Intensive Care Medicine</i> , 2018, 44, 1982-1984.	3.9	3
43	Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 566-577.	1.3	40
44	T2Bacteria magnetic resonance assay for the rapid detection of ESKAPEc pathogens directly in whole blood. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, iv20-iv26.	1.3	64
45	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw513.	1.3	46
46	Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. <i>Virulence</i> , 2017, 8, 470-484.	1.8	97
47	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , 2017, 43, 509-518.	3.9	51
48	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	4.6	367
49	SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2859-2864.	0.6	6
50	Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. A multicentric study. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 768-774.	0.6	29
51	Invasive <i>Candida</i> Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. <i>Transplantation Direct</i> , 2017, 3, e156.	0.8	34
52	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. <i>Journal of Chemotherapy</i> , 2017, 29, 197-214.	0.7	81
53	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. <i>Haematologica</i> , 2017, 102, e407-e410.	1.7	17
54	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	1.1	8

#	ARTICLE	IF	CITATIONS
55	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. <i>Surgical Infections</i> , 2017, 18, 846-853.	0.7	31
56	Antibodies against a β -glucan-protein complex of <i>Candida albicans</i> and its potential as indicator of protective immunity in candidemic patients. <i>Scientific Reports</i> , 2017, 7, 2722.	1.6	12
57	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	2.8	98
58	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	2.9	43
59	Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx063.	0.4	44
60	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , 2017, 12, 34.	2.1	47
61	Combined use of serum (1,3)- β -d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. <i>Critical Care</i> , 2017, 21, 176.	2.5	65
62	Characteristics of <i>Staphylococcus aureus</i> Bacteraemia and Predictors of Early and Late Mortality. <i>PLoS ONE</i> , 2017, 12, e0170236.	1.1	67
63	(1,3)- β -D-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2262-2269.	1.3	73
64	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	1.4	137
65	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	1.4	89
66	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. <i>European Journal of Internal Medicine</i> , 2016, 34, 45-53.	1.0	8
67	Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. <i>American Journal of Hematology</i> , 2016, 91, 1076-1081.	2.0	115
68	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. <i>Critical Care</i> , 2016, 20, 246.	2.5	9
69	Comment on: Mortality due to <i>bla</i> KPC <i>Klebsiella pneumoniae</i> bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1743.1-1744.	1.3	6
70	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	1.3	41
71	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. <i>Blood</i> , 2016, 128, 3700-3700.	0.6	0
72	Multidrug-resistant bacteria and bloodstream infections in onco-hematological patients. <i>Journal of Chemotherapy</i> , 2015, 27, 250-252.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <sc>SEIFEM</sc> registry. British Journal of Haematology, 2015, 170, 434-439.	1.2	14
74	Fungal infections in the ICU. Current Opinion in Critical Care, 2015, 21, 421-429.	1.6	32
75	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	1.7	64
76	Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Medicine, 2015, 41, 103-110.	3.9	37
77	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	3.9	165
78	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	1.3	434
79	Antifungal Susceptibility Profiles of Bloodstream Yeast Isolates by Sensititre YeastOne over Nine Years at a Large Italian Teaching Hospital. Antimicrobial Agents and Chemotherapy, 2015, 59, 3944-3955.	1.4	68
80	Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Medicine, 2015, 41, 776-795.	3.9	133
81	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study – authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2922-2922.	1.3	60
82	Reply to Wong et al. Clinical Infectious Diseases, 2015, 61, 1352-1352.	2.9	1
83	Bloodstream Infections Caused By <i>Klebsiella pneumoniae</i> in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey. Blood, 2015, 126, 3757-3757.	0.6	3
84	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. Blood, 2015, 126, 1023-1023.	0.6	0
85	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	0.6	1
86	Carbapenemase-producing <i>Klebsiella pneumoniae</i> and Hematologic Malignancies. Emerging Infectious Diseases, 2014, 20, 1235-1236.	2.0	48
87	Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer. Current Opinion in Infectious Diseases, 2014, 27, 200-210.	1.3	125
88	Relapsing bloodstream infections during treatment of acute leukemia. Annals of Hematology, 2014, 93, 785-790.	0.8	19
89	Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2014, 58, 851-858.	1.4	91
90	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	1.4	75

#	ARTICLE	IF	CITATIONS
91	High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. <i>Critical Care</i> , 2014, 18, R90.	2.5	192
92	Performance of Two Resin-Containing Blood Culture Media in Detection of Bloodstream Infections and in Direct Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) Broth Assays for Isolate Identification: Clinical Comparison of the BacT/Alert Plus and Bactec Plus Systems. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3558-3567.	1.8	48
93	Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3142-3147.	1.3	21
94	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2014, 40, 839-845.	3.9	209
95	Response. <i>Chest</i> , 2014, 145, 927-928.	0.4	0
96	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2014, 124, 3880-3880.	0.6	9
97	Invasive Fungal Infections in Acute Promyelocytic Leukemia Patients. Results of a Prospective Multicenter Study in Italy. <i>Blood</i> , 2014, 124, 3682-3682.	0.6	0
98	Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain. <i>Journal of Clinical Microbiology</i> , 2013, 51, 4167-4172.	1.8	176
99	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. <i>Intensive Care Medicine</i> , 2013, 39, 2092-2106.	3.9	169
100	Predictors of mortality in multidrug-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1053-1063.	2.0	82
101	Clinical outcomes of <i>Pseudomonas aeruginosa</i> pneumonia in intensive care unit patients. <i>Intensive Care Medicine</i> , 2013, 39, 682-692.	3.9	137
102	Effect of Aerosolized Colistin as Adjunctive Treatment on the Outcomes of Microbiologically Documented Ventilator-Associated Pneumonia Caused by Colistin-Only Susceptible Gram-Negative Bacteria. <i>Chest</i> , 2013, 144, 1768-1775.	0.4	150
103	Mortality in patients with early- or late-onset candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 927-935.	1.3	37
104	Why Should We Monitor (1-3)- β -D-Glucan Levels during Invasive Candidiasis? Just Ask Your Ophthalmologist!. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1645-1646.	1.8	7
105	Reply to "Identifying Patients Harboring Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae on Hospital Admission Is Not That Simple". <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2220-2220.	1.4	1
106	Severe pneumonia in intensive care. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 213-221.	1.2	34
107	High-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis Caused by Staphylococcal Small-Colony Variants. <i>Clinical Infectious Diseases</i> , 2012, 54, 1516-1517.	2.9	12
108	Predictors of Mortality in Bloodstream Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : Importance of Combination Therapy. <i>Clinical Infectious Diseases</i> , 2012, 55, 943-950.	2.9	855

#	ARTICLE	IF	CITATIONS
109	Safety and Effectiveness of Transvenous Lead Extraction in Octogenarians. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1103-1108.	0.8	25
110	Neurological involvement during legionellosis, look beyond the lung. <i>Journal of Neurology</i> , 2012, 259, 2243-2245.	1.8	3
111	Direct MALDI-TOF Mass Spectrometry Assay of Blood Culture Broths for Rapid Identification of <i>Candida</i> Species Causing Bloodstream Infections: an Observational Study in Two Large Microbiology Laboratories. <i>Journal of Clinical Microbiology</i> , 2012, 50, 176-179.	1.8	190
112	Detecting risk and predicting patient mortality in patients with extended-spectrum β -lactamase-producing <i>Enterobacteriaceae</i> bloodstream infections. <i>Future Microbiology</i> , 2012, 7, 1173-1189.	1.0	55
113	Multidrug-Resistant <i>Proteus mirabilis</i> Bloodstream Infections: Risk Factors and Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3224-3231.	1.4	51
114	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. <i>Clinical Infectious Diseases</i> , 2012, 55, 1515-1521.	2.9	77
115	Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. <i>PLoS ONE</i> , 2012, 7, e33705.	1.1	170
116	Evaluation of the New NucliSENS EasyQ KPC Test for Rapid Detection of <i>Klebsiella pneumoniae</i> Carbapenemase Genes (<i>bla</i> _{KPC}). <i>Journal of Clinical Microbiology</i> , 2012, 50, 2783-2785.	1.8	38
117	Derivation and Validation of a Scoring System to Identify Patients with Bacteremia and Hematological Malignancies at Higher Risk for Mortality. <i>PLoS ONE</i> , 2012, 7, e51612.	1.1	18
118	Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1 \rightarrow 3)- β -D-glucan assay, <i>Candida</i> score, and colonization index. <i>Critical Care</i> , 2011, 15, R249.	2.5	152
119	Uncommon yeast infections in hematological patients: from diagnosis to treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1067-1075.	2.0	18
120	The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. <i>Haematologica</i> , 2011, 96, 1366-1370.	1.7	56
121	Estheseoneuroblastoma in an HIV-1 Infected Patient: Case Report. <i>Skull Base Reports</i> , 2011, 1, 129-132.	0.0	0
122	Etiology of Febrile Episodes in Patients With Acute Myeloid Leukemia: Results From the Hema e-Chart Registry. <i>Archives of Internal Medicine</i> , 2011, 171, 1502.	4.3	27
123	Multidrug resistant <i>Pseudomonas aeruginosa</i> bloodstream infection in adult patients with hematologic malignancies. <i>Haematologica</i> , 2011, 96, e1-e3.	1.7	67
124	Identifying Patients Harboring Extended-Spectrum- β -Lactamase-Producing <i>Enterobacteriaceae</i> on Hospital Admission: Derivation and Validation of a Scoring System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3485-3490.	1.4	137
125	In Vitro Activities of Anidulafungin and Other Antifungal Agents against Biofilms Formed by Clinical Isolates of Different <i>Candida</i> and <i>Aspergillus</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3031-3035.	1.4	67
126	Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum- β -Lactamase Production and Inadequate Initial Antibiotic Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4085-4091.	1.4	185

#	ARTICLE	IF	CITATIONS
127	Fluconazole Use as an Important Risk Factor in the Emergence of Fluconazole-Resistant <i>Candida glabrata</i> Fungemia. <i>Archives of Internal Medicine</i> , 2009, 169, 1444.	4.3	5
128	Incidence and clinical impact of extended-spectrum- β -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	1.7	144
129	Factors associated with mortality in bacteremic patients with hematologic malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 320-326.	0.8	82
130	Oral lesions in HIV and HCV coinfected individuals in HAART era. <i>Journal of Oral Pathology and Medicine</i> , 2008, 37, 468-474.	1.4	10
131	Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> : Risk Factors for Inadequate Initial Antimicrobial Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3244-3252.	1.4	104
132	Fungaemia caused by <i>Candida glabrata</i> with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1379-1385.	1.3	50
133	Oral Lichenoid Lesions in HIV-HCV-Coinfected Subjects During Antiviral Therapy: 2 Cases and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2008, 30, 466-471.	0.3	18
134	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1987-1994.	1.4	382
135	Biofilm Production by <i>Candida</i> Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1843-1850.	1.8	300
136	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3469-3469.	1.4	5
137	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 325-331.	0.8	104
138	Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 875-885.	2.0	22
139	Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. <i>AIDS Research and Therapy</i> , 2006, 3, 22.	0.7	33
140	Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing <i>Klebsiella pneumoniae</i> : Risk Factors, Molecular Epidemiology, and Clinical Outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 498-504.	1.4	243
141	Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3257-3262.	1.8	57
142	Azole Resistance of <i>Candida glabrata</i> in a Case of Recurrent Fungemia. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3046-3047.	1.8	27
143	ESBL-producing multidrug-resistant <i>Providencia stuartii</i> infections in a university hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 277-282.	1.3	68
144	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy. <i>BMC Infectious Diseases</i> , 2004, 4, 46.	1.3	65

#	ARTICLE	IF	CITATIONS
145	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , 2004, 18, 1602-1604.	1.0	2
146	Older HIV-positive patients in the era of highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 128-131.	1.0	55
147	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 765-768.	1.0	54
148	Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitution-Independent Beneficial Effect on <i>Candida</i> Virulence and Oral Candidiasis in Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2002, 185, 188-195.	1.9	79
149	Azole Susceptibility Patterns and Genetic Relationship Among Oral <i>Candida</i> Strains Isolated in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 38-44.	0.9	17
150	Risk factors and predictors of mortality of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteraemia in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 375-382.	1.3	66
151	Multidrug-Resistant <i>Pseudomonas Aeruginosa</i> Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology. <i>Emerging Infectious Diseases</i> , 2002, 8, 220-221.	2.0	75
152	Glycopeptide Resistance among Coagulase-Negative <i>Staphylococci</i> that Cause Bacteremia: Epidemiological and Clinical Findings from a Case-Control Study. <i>Clinical Infectious Diseases</i> , 2001, 33, 1628-1635.	2.9	48
153	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 145-151.	0.9	15
154	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 145-151.	0.9	54
155	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. <i>Aids</i> , 2000, 14, 2948-2949.	1.0	20
156	Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 21, 20-25.	0.9	126
157	In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors. <i>Journal of Infectious Diseases</i> , 1999, 180, 448-453.	1.9	205
158	HIV-Associated Bacterial Pneumonia in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 208-209.	0.3	20
159	Highly Active Antiretroviral Therapy Decreases the Incidence of Bacteremia in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 1998, 27, 901-902.	2.9	21
160	Nosocomial Bloodstream Infections in HIV-Infected Patients: Attributable Mortality and Extension of Hospital Stay. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 490-497.	0.3	32
161	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 307-310.	0.8	26
162	Osteoarticular bacterial infections are rare in HIV-infected patients: 14 cases found among 4,023 HIV-infected patients. <i>Acta Orthopaedica</i> , 1997, 68, 554-558.	1.4	35

#	ARTICLE	IF	CITATIONS
163	Age as a prognostic factor in AIDS. Lancet, The, 1996, 348, 623-624.	6.3	9
164	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Journal of Antimicrobial Chemotherapy, 1996, 38, 691-699.	1.3	55
165	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunology Letters, 1995, 47, 223-226.	1.1	7
166	Primary central nervous system lymphoma and brain biopsy in AIDS. Lancet, The, 1993, 341, 1411-1412.	6.3	15
167	Synthetic Peptides Corresponding to Sequences in HIV Envelope gp41 and gp120 Enhance In Vitro Production of Interleukin-1 and Tumor Necrosis Factor but Depress Production of Interferon- α , Interferon- β and Interleukin-2. Viral Immunology, 1991, 4, 33-42.	0.6	41
168	A national voice for information about HIV infections: The Italian state AIDS hot-line. Public Health, 1989, 103, 447-454.	1.4	0
169	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cellular Immunology, 1988, 115, 57-65.	1.4	52